High Mark Wealth Management LLC Mei Pharma, Inc. Transaction History

High Mark Wealth Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 01, 2023	SELL	$0.22 - $8.4 $2,200 - $84,000	-10,000 Reduced 48.54%	10,600 $2,000
Q3 2022 Oct 21, 2022	SELL	$0.41 - $8.8 $893 - $19,184	-2,180 Reduced 9.57%	20,600 $8,000
Q2 2022 Jul 19, 2022	SELL	$0.42 - $0.65 $344 - $533	-820 Reduced 3.47%	22,780 $14,000
Q4 2021 Jan 20, 2022	SELL	$2.33 - $3.37 $6,810 - $9,850	-2,923 Reduced 11.02%	23,600 $63,000
Q3 2021 Nov 01, 2021	BUY	$2.52 - $2.99 $887 - $1,052	352 Added 1.35%	26,523 $73,000
Q2 2021 Aug 02, 2021	BUY	$2.6 - $3.65 $56,646 - $79,522	21,787 Added 496.97%	26,171 $59,000
Q1 2021 Apr 22, 2021	SELL	$2.73 - $4.5 $1,302 - $2,146	-477 Reduced 9.81%	4,384 $15,000
Q4 2020 Jan 27, 2021	SELL	$2.6 - $3.32 $30,511 - $38,960	-11,735 Reduced 70.71%	4,861 $13,000
Q3 2020 Oct 26, 2020	BUY	$2.46 - $4.27 $40,826 - $70,864	16,596 New	16,596 $52,000

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $370M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of High Mark Wealth Management LLC, based on Form 13F filings with the SEC.

Stay updated on High Mark Wealth Management LLC with notifications on news.